PAPS paperCorrelation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification
Section snippets
Patient clinical data and biological data of NB samples
Patients with NB, evaluated in the Department of Pediatric Surgery in Kyushu University, were diagnosed between April 1988 and March 2008. The tumors were staged according to the International Neuroblastoma Staging System (INSS). All of the parents of the patients provided their informed consent for tumor preservation and the biological analysis before surgery. We have obtained the comprehensive agreement for all samples. This study was performed according to ethical guidelines for clinical
SCAs and MYCN gene amplifications
Nine of 54 samples showed MYCN amplification. All 9 samples with MYCN amplification (group 1) and 20 of 45 samples without MYCN amplification showed diploidy/tetraploidy (group 2), and other 25 samples without MYCN amplification showed aneuploidy (group 3). One or more SCAs were detected in 37 (68.5%) of all 54 samples. In all 54 samples, the most frequently observed SCAs were 17q gain (26/54; 48.1%) and 11q loss (16/54; 29.6%), followed by 1p loss (15/54; 27.8%) (Table 2). The 1p loss and 17q
Discussion
In the present study, the number of SCAs such as 11q loss, 17q gain, and 1p loss, significantly increased in proportion to the age at diagnosis in patients with diploid/tetraploid NBs without MYCN amplification. Spitz et al [13] previously reported that 11q and 3p loss were also associated with advanced stage disease and that the children with 11q deletion and 3p deletion were older than those with normal 11q and normal 3q loss. 17q gain was reported to be associated with factors related to a
Acknowledgments
The authors thank Dr. Ken Yamamoto for helpful discussions and thank Brian Quinn for reading and editing the manuscript.
References (15)
- et al.
Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982-1992
Eur J Cancer
(2000) - et al.
Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan
J Pediatr Surg
(2009) - et al.
Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
N Engl J Med
(1984) - et al.
Biology and genetics of human neuroblastomas
J Pediatr Hematol Oncol
(1997) - et al.
Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage
Science
(1984) - et al.
Association of multiple copies of the Nmyc oncogene with rapid progression of neuroblastomas
N Engl J Med
(1985) - et al.
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
Oncogene
(1999)
Cited by (4)
Neuroblastoma
2013, Cancer Genomics: From Bench to Personalized MedicineNeuroblastoma in adults: Diagnosis and treatment
2014, Chinese Journal of Clinical OncologyUltra-high density snparray in neuroblastoma molecular diagnostics
2014, Frontiers in Oncology
Presented at the Pacific Association of Pediatric Surgeons 44th Annual Meeting, Cancun, Mexico, April 10-14, 2011.